Related Experiment Video
Updated: Sep 23, 2026
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses
Hideto Kimata1, Hiroki Takakuwa, Fumi Goshima
1Laboratory of Virology, Research Institute for Disease, Mechanism and Control, Department of Surgery II, Graduate School of Medicine, Nagoya University, Showa-ku, Nagoya 466-8550, Japan.
Background/Aims:
Oncolytic herpes simplex virus type 1 mutants are promising therapeutic agents for malignant tumors. Their efficacy depends on the extent of both viral replication in the tumor and induction of a host anti-tumor immune response. In this study, new replication-competent, attenuated herpes simplex virus mutants, named HF10 and Hh101, have been evaluated for their oncolytic activities.
Methodology:
We determined the genome structures of the mutants and examined the survival rates of mice that were injected intraperitoneally with carcinoma and sarcoma cells and treated with the mutants. Tumors were examined by both histology and immunochemistry.
Results:
HF10 and Hh101 administration effectively treated disseminated peritoneal colon carcinoma in a BALB/c mouse model and all surviving mice were resistant to rechallenge of the tumor cells. The survival rate in a C3H mouse model was improved by HF10, but not Hh101.
Conclusions:
HF10 and Hh101, novel agents as oncolytic viral therapy, are both safe and effective herpes simplex virus mutants for malignant tumor treatment. The Hh101, is more attenuated in its virulence than the HF10 because it is a double gene knocking-out construct. The choice of viral mutant for treatment should be made according to the type of malignancy.
Insights
New herpes simplex virus (HSV) mutants, HF10 and Hh101, show promise for oncolytic viral therapy. These safe and effective HSV mutants demonstrate efficacy in treating malignant tumors and inducing anti-tumor immunity.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Oncolytic herpes simplex virus type 1 (HSV-1) mutants are investigated for cancer therapy.
- Therapeutic efficacy relies on viral replication within tumors and stimulating host anti-tumor immune responses.
Purpose of the Study:
- To evaluate the oncolytic activities of novel replication-competent, attenuated HSV mutants, HF10 and Hh101.
- To assess their safety and effectiveness in treating malignant tumors.
Main Methods:
- Genome structures of HF10 and Hh101 mutants were determined.
- Mice with disseminated peritoneal carcinoma and sarcoma were treated with the mutants.
- Tumor histology and immunohistochemistry were used for examination.
Main Results:
- HF10 and Hh101 effectively treated disseminated peritoneal colon carcinoma in a BALB/c mouse model.
- Surviving mice in the BALB/c model developed resistance to tumor cell rechallenge.
- HF10 improved survival rates in a C3H mouse model, while Hh101 did not.
Conclusions:
- HF10 and Hh101 represent novel, safe, and effective HSV mutants for oncolytic viral therapy.
- Hh101 exhibits greater attenuation than HF10 due to its double gene knockout.
- The selection of an appropriate viral mutant should be tailored to the specific type of malignancy.
Related Concept Videos
01:28Herpes
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...